Denmark reassesses rejection of Novartis cancer combination to include more exceptions

The Danish Medicines Council has re-evaluated a combination treatment application from Novartis that it rejected in 2018. The answer is still no, but there are now more exceptions attached.
Photo: Arnd Wiegmann/Reuters/Ritzau Scanpix
Photo: Arnd Wiegmann/Reuters/Ritzau Scanpix
by albert rønning-andersson, translated by daniel pedersen

Members of the Danish Medicines Council have said no to an application from Novartis, which was hoping to see drugs Tafinlar (dabrafenib) and Mekinist (trametinib) approved as a as standard combination treatment for stage III melanoma with the BRAF V600 mutation, the council reports on its website.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading